Test Code F_9 Coagulation Factor IX Activity Assay, Plasma
Reporting Name
Coag Factor IX Assay, PUseful For
Diagnosing deficiencies, particularly hemophilia B (Christmas disease)
Assessing the impact of liver disease on hemostasis
Investigation of a prolonged activated partial thromboplastin time
Performing Laboratory
Mayo Clinic Laboratories in RochesterSpecimen Type
Plasma Na CitOrdering Guidance
Coagulation testing is highly complex, often requiring the performance of multiple assays and correlation with clinical information. For that reason, consider ordering a Coagulation Consultation.
Necessary Information
If priority specimen, mark request form, give reason, and request a call-back.
Specimen Required
Specimen Type: Platelet-poor plasma
Patient Preparation: Patient must not be receiving Coumadin (warfarin) or heparin therapy.
Collection Container/Tube: Light-blue top (3.2% sodium citrate)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Specimen must be collected prior to factor replacement therapy.
2. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing.
3. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.
4. Aliquot plasma into a plastic vial, leaving 0.25 mL in the bottom of centrifuged vial.
5. Freeze plasma immediately (no longer than 4 hours after collection) at -20° C or ideally, at or below -40° C.
Additional Information:
1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.
2. Each coagulation assay requested should have its own vial.
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Plasma Na Cit | Frozen | 14 days |
Special Instructions
Day(s) Performed
Monday through Saturday
Test Classification
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
85250
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
F_9 | Coag Factor IX Assay, P | 3187-2 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
F_9 | Coag Factor IX Assay, P | 3187-2 |
Clinical Information
Factor IX is a vitamin K-dependent serine protease synthesized in the liver and participates in the intrinsic coagulation pathway. Its biological half-life is 18 to 24 hours.
Congenital deficiency is inherited as an X-linked recessive bleeding disorder (hemophilia B). Severe deficiency (<1%) is characterized by hemarthroses, deep tissue bleeding, excessive bleeding with trauma, and ecchymoses.
Acquired deficiency is associated with liver disease, vitamin K deficiency, warfarin therapy, and inhibitors (rare).
Cautions
Liver disease, warfarin therapy, or vitamin K deficiency may decrease factor IX levels.
Report Available
1 to 3 daysSpecimen Retention Time
7 daysReject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Testing Algorithm
For information see Hemophilia Testing Algorithm
Method Name
Optical Clot-Based
Forms
If not ordering electronically, complete, print, and send a Coagulation Test Request (T753) with the specimen.